Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jae-Soo Shin

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Cancer Medicine|March 27, 2018
Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemiaHayeon Noh, Su Young Jung, Jae-Yong Kwak, et al.
International Immunopharmacology|January 10, 2006
Enantiomers of higenamine inhibit LPS-induced iNOS in a macrophage cell line and improve the survival of mice with experimental endotoxemiaJee Eun Park, Young Jin Kang, Min Kyu Park, et al.
Human Molecular Genetics|June 14, 2018
The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse modelSaebom Lee, Sangjune Kim, Yong Joo Park, et al.
Journal of Virology|June 7, 2019
Novel Small Molecule Targeting the Hemagglutinin Stalk of Influenza VirusesJin Il Kim, Sangmoo Lee, Gong Yeal Lee, et al.
Haematologica|April 8, 2014
Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitorsSung-Hyun Kim, Hari Menon, Saengsuree Jootar, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Cancer Medicine|March 27, 2018
Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemiaHayeon Noh, Su Young Jung, Jae-Yong Kwak, et al.
International Immunopharmacology|January 10, 2006
Enantiomers of higenamine inhibit LPS-induced iNOS in a macrophage cell line and improve the survival of mice with experimental endotoxemiaJee Eun Park, Young Jin Kang, Min Kyu Park, et al.
Human Molecular Genetics|June 14, 2018
The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse modelSaebom Lee, Sangjune Kim, Yong Joo Park, et al.
Journal of Virology|June 7, 2019
Novel Small Molecule Targeting the Hemagglutinin Stalk of Influenza VirusesJin Il Kim, Sangmoo Lee, Gong Yeal Lee, et al.
Haematologica|April 8, 2014
Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitorsSung-Hyun Kim, Hari Menon, Saengsuree Jootar, et al.
Pageof 3